The ritual of Dia de los Muertos (Day of the Dead) has roots…
Questions
The rituаl оf Diа de lоs Muertоs (Dаy of the Dead) has roots in:
InstructiоnsReаd eаch questiоn cаrefully.Answer each questiоn by bubbling your answer on the Scantron answer sheet.After you have finished answering all questions, select TRUE.Click Finish Attempt at the bottom of the page.On the next page, click Submit All and Finish.If a confirmation message appears, click Submit All and Finish again to complete your submission.Once your assessment has been submitted successfully, notify your proctor that you are finished. Please wait for the proctor's instructions before proceeding to the next step.Chapters 16-21 Key/Variation B____ 1. What neurotransmitter mechanism accounts for the central nervous system stimulation produced by amphetamine medications? a. Amphetamines enhance the binding of serotonin to postsynaptic receptors in the medulla oblongata and brain stem regions c. Amphetamines stimulate the release of norepinephrine and dopamine from the brain and block the reuptake of these neurotransmitters b. Amphetamines activate cholinergic receptors in the hypothalamus and suppress acetylcholinesterase enzyme activity throughout the central nervous system d. Amphetamines inhibit the reuptake of gamma-aminobutyric acid and glutamate from synaptic terminals in the cerebral cortex and limbic system ____ 2. What therapeutic plasma level range must be maintained for phenytoin to ensure drug effectiveness while preventing toxicity? a. Phenytoin therapeutic range is 10 to 20 mcg/mL with levels above this range potentially resulting in drug toxicity c. Phenytoin therapeutic range is 20 to 30 mcg/mL with levels below this range indicating subtherapeutic dosing b. Phenytoin therapeutic range is 5 to 10 mcg/mL with levels below this range indicating adequate seizure control d. Phenytoin therapeutic range is 30 to 40 mcg/mL with levels above this range requiring immediate dosage increase ____ 3. What dosing recommendation should guide benzodiazepine hypnotic therapy for older adults to minimize adverse effects and dependency risk? a. Older adults should take prescribed benzodiazepines no more than four times weekly and select specific nights for administration c. Older adults should take prescribed benzodiazepines in divided doses throughout the day to ensure continuous anxiolytic coverage b. Older adults should take prescribed benzodiazepines daily without interruption to maintain steady-state plasma concentrations d. Older adults should take prescribed benzodiazepines only during daytime hours to prevent nocturnal confusion and disorientation ____ 4. What clinical conditions differentiate the therapeutic use of muscle relaxants for spasticity from those used for muscle spasms? a. Spasticity muscle relaxants treat acute traumatic injuries and postoperative pain while muscle spasm relaxants treat chronic debilitating disorders such as stroke c. Spasticity muscle relaxants treat chronic debilitating disorders such as multiple sclerosis and cerebral palsy while muscle spasm relaxants treat acute traumatic injuries b. Spasticity muscle relaxants treat peripheral nerve compression syndromes and radiculopathy while muscle spasm relaxants treat central nervous system degenerative diseases d. Spasticity muscle relaxants treat temporary musculoskeletal strain and overuse injuries while muscle spasm relaxants treat permanent neurological demyelination disorders ____ 5. What autoimmune mechanism differentiates the pathophysiology of myasthenia gravis from multiple sclerosis? a. Myasthenia gravis involves autoimmune attack on oligodendrocytes in the brain while multiple sclerosis involves destruction of acetylcholine synthesis pathways c. Myasthenia gravis involves antibody destruction of gamma-aminobutyric acid receptors while multiple sclerosis involves autoimmune attack on neuromuscular junction proteins b. Myasthenia gravis involves antibody attack on acetylcholine receptors at neuromuscular junctions while multiple sclerosis involves autoimmune destruction of myelin sheaths d. Myasthenia gravis involves autoimmune destruction of myelin sheaths in peripheral nerves while multiple sclerosis involves antibody attack on dopamine receptors ____ 6. What pathophysiological characteristic distinguishes attention-deficit/hyperactivity disorder (ADHD) from narcolepsy as neurological conditions? a. ADHD involves progressive neurodegeneration of the basal ganglia, while narcolepsy involves autoimmune destruction of hypothalamic orexin-producing neurons c. ADHD involves hyperactivity of gamma-aminobutyric acid pathways, while narcolepsy involves deficiency of acetylcholine in the reticular activating system b. ADHD involves overproduction of melatonin during daytime hours, while narcolepsy involves underproduction of cortisol from adrenal insufficiency d. ADHD involves dysregulation of serotonin, norepinephrine, and dopamine transmitters, while narcolepsy involves excessive daytime sleepiness and sudden sleep attacks ____ 7. What feature differentiates generalized seizures from focal seizures in terms of neuronal involvement and origin? a. Generalized seizures originate from abnormal electrical activity in one hemisphere with potential secondary spread to bilateral involvement c. Generalized seizures involve both cerebral hemispheres from onset with abnormal electrical discharges affecting widespread brain areas b. Generalized seizures begin in localized cortical areas with impaired awareness and automatisms as primary manifestations d. Generalized seizures originate in specific brain regions with preserved consciousness and isolated motor or sensory symptoms ____ 8. What pharmacological mechanism do acetylcholinesterase inhibitors utilize to improve muscle strength in patients with myasthenia gravis? a. Acetylcholinesterase inhibitors block antibody production at neuromuscular junctions to prevent further destruction of acetylcholine receptor sites c. Acetylcholinesterase inhibitors enhance dopamine release at neuromuscular junctions to compensate for decreased acetylcholine receptor availability b. Acetylcholinesterase inhibitors prevent acetylcholine destruction to promote neuromuscular impulse transmission across myoneural junctions d. Acetylcholinesterase inhibitors stimulate synthesis of new acetylcholine receptors to replace damaged receptor sites at neuromuscular junctions ____ 9. What nonpharmacologic intervention should be prioritized before prescribing sleep medications for older adults experiencing insomnia? a. Prescribing long-acting benzodiazepines such as flurazepam and diazepam to ensure uninterrupted sleep throughout the night c. Identifying the underlying cause of insomnia and implementing behavioral sleep hygiene modifications before medication initiation b. Scheduling daytime napping periods at regular intervals to compensate for nighttime sleep deficits and reduce fatigue d. Increasing evening fluid intake and caffeine consumption to promote alertness during nighttime bathroom visits ____ 10. What central nervous system side effect is shared among amphetamines, anorexiants, and analeptics as a result of their stimulant properties? a. Restlessness and insomnia resulting from increased central nervous system stimulation and heightened alertness c. Confusion and disorientation resulting from anticholinergic effects and impaired cognitive processing b. Sedation and drowsiness resulting from decreased cerebral cortex activity and reduced neuronal firing rates d. Bradyphrenia and psychomotor retardation resulting from dopamine receptor blockade and reduced motor coordination ____ 11. What essential patient teaching point should nurses emphasize regarding antiseizure medication adherence to prevent seizure recurrence? a. Patients should take antiseizure medications only during periods of increased stress or when experiencing seizure aura symptoms c. Patients should take antiseizure medications consistently at prescribed times without abruptly discontinuing therapy to prevent breakthrough seizures b. Patients should adjust antiseizure medication doses based on daily seizure frequency to maintain optimal therapeutic effectiveness d. Patients should discontinue antiseizure medications gradually over two weeks when seizure-free for three consecutive months ____ 12. What therapeutic classification represents the first-line treatment approach for disease modification in patients with multiple sclerosis? a. Monoclonal antibodies function as first-line disease-modifying drugs that slow disease progression and prevent relapses through B-cell depletion c. Corticosteroids function as first-line disease-modifying drugs that slow disease progression and prevent relapses through anti-inflammatory mechanisms b. Immunosuppressants function as first-line disease-modifying drugs that slow disease progression and prevent relapses through lymphocyte cytotoxicity d. Immunomodulators function as first-line disease-modifying drugs that slow disease progression and prevent relapses through immune system modulation ____ 13. What characteristic defines the stage of anesthesia during which the surgical procedure is typically performed? a. Stage three surgical characterized by four phases with surgery performed in phase two and upper phase three as respirations become shallower c. Stage two excitement characterized by loss of consciousness, cerebral cortex depression, and confusion or delirium with short induction time b. Stage one analgesia characterized by consciousness loss, difficult speech, and loss of pain sensation with possible hallucinations d. Stage four medullary paralysis characterized by toxic anesthesia effects with respiratory loss and circulatory collapse requiring ventilatory assistance ____ 14. What adverse effect describes residual drowsiness experienced in the morning after taking an intermediate-acting hypnotic medication? a. Tolerance resulting from decreased receptor sensitivity and upregulation of hepatic enzyme systems over time c. Hangover resulting from residual drug effects and unmetabolized medication remaining in the central nervous system b. Dependence resulting from neuroadaptation and physiologic requirement for continued medication to maintain homeostasis d. Withdrawal resulting from abrupt medication cessation and rebound central nervous system hyperexcitability ____ 15. What complication requires monitoring after spinal anesthesia administration due to cerebrospinal fluid leakage at the needle insertion site? a. Malignant hyperthermia occurring within minutes of anesthetic exposure with treatment including dantrolene sodium and aggressive cooling measures c. Respiratory depression occurring during anesthetic administration with treatment including supplemental oxygen and mechanical ventilation support b. Cardiovascular toxicity occurring immediately after injection with treatment including lipid emulsion therapy and advanced cardiac life support d. Postdural puncture headache occurring 6 to 48 hours after dural puncture with treatment including analgesics and increased fluids ____ 16. What distinguishing characteristic differentiates ramelteon from benzodiazepine and nonbenzodiazepine hypnotics in terms of regulatory classification? a. Ramelteon is not classified as a controlled substance and represents the first FDA-approved hypnotic with this designation c. Ramelteon is classified as a Schedule IV controlled substance similar to benzodiazepines and requires prescription monitoring b. Ramelteon is classified as a Schedule II controlled substance requiring triplicate prescriptions and mandatory reporting d. Ramelteon is classified as an over-the-counter medication available without prescription or healthcare provider supervision ____ 17. What neurotransmitter imbalance characterizes the pathophysiology of Parkinson disease at the level of the striatum? a. Parkinson disease results from decreased dopamine and increased acetylcholine activity leading to excessive neuronal excitation and motor symptoms c. Parkinson disease results from increased dopamine and decreased acetylcholine activity leading to reduced inhibition of motor pathways b. Parkinson disease results from increased serotonin and decreased norepinephrine activity leading to progressive cognitive and motor decline d. Parkinson disease results from decreased gamma-aminobutyric acid and increased dopamine activity leading to hyperkinetic movement disorders ____ 18. What mechanism of action explains the therapeutic effects of benzodiazepines in treating anxiety and insomnia? a. Benzodiazepines block the reuptake of serotonin and norepinephrine at presynaptic nerve terminals to enhance mood stabilization c. Benzodiazepines stimulate dopamine release in the mesolimbic pathway to enhance reward system activation b. Benzodiazepines inhibit monoamine oxidase enzymes in the synaptic cleft to prevent neurotransmitter degradation d. Benzodiazepines increase the action of gamma-aminobutyric acid at GABA receptors to reduce neuron excitability ____ 19. What mechanism of action distinguishes barbiturates from hydantoins in the treatment of seizure disorders? a. Barbiturates inhibit sodium influx and stabilize cell membranes to reduce repetitive neuronal firing and limit seizure activity c. Barbiturates increase electrical stimulation threshold in cardiac tissue to provide antidysrhythmic effects and seizure control b. Barbiturates enhance gamma-aminobutyric acid activity to increase inhibitory neurotransmission and reduce seizure occurrence d. Barbiturates block calcium channels in thalamic neurons to suppress abnormal electrical discharges associated with absence seizures ____ 20. What therapeutic indication supports prescribing lorazepam or diazepam for patients experiencing sleep disturbances? a. Lorazepam and diazepam treat insomnia caused by respiratory depression through bronchodilation effects c. Lorazepam and diazepam treat insomnia caused by circadian rhythm disruption through melatonin receptor agonism b. Lorazepam and diazepam treat insomnia caused by increased anxiety through their anxiolytic properties d. Lorazepam and diazepam treat insomnia caused by pain syndromes through opioid receptor activation ____ 21. What gastrointestinal side effect distinguishes caffeine from amphetamines when comparing their adverse reaction profiles? a. Gastric ulceration and hemorrhage occurring exclusively with caffeine use due to prostaglandin inhibition c. Gastrointestinal irritation and nausea occurring with caffeine use but not typically associated with amphetamine administration b. Biliary obstruction and cholestasis occurring with caffeine use but not reported with amphetamine administration d. Severe constipation and decreased bowel motility occurring with caffeine use but not with amphetamine administration ____ 22. What therapeutic outcome differentiates the use of methylphenidate in treating attention-deficit/hyperactivity disorder (ADHD) versus narcolepsy? a. In ADHD, methylphenidate stimulates acetylcholine release and decreases restlessness, while in narcolepsy, methylphenidate inhibits histamine receptors and prevents cataplexy c. In ADHD, methylphenidate decreases hyperactivity and improves attention span, while in narcolepsy, methylphenidate promotes wakefulness and reduces sleep attacks b. In ADHD, methylphenidate blocks serotonin receptors and reduces impulsivity, while in narcolepsy, methylphenidate activates GABA pathways and prolongs sleep latency d. In ADHD, methylphenidate suppresses dopamine reuptake and increases sedation, while in narcolepsy, methylphenidate enhances melatonin production and regulates circadian rhythm ____ 23. What dosing recommendation should guide benzodiazepine hypnotic therapy for older adults to minimize adverse effects and dependency risk? a. Older adults should take prescribed benzodiazepines only during daytime hours to prevent nocturnal confusion and disorientation c. Older adults should take prescribed benzodiazepines in divided doses throughout the day to ensure continuous anxiolytic coverage b. Older adults should take prescribed benzodiazepines no more than four times weekly and select specific nights for administration d. Older adults should take prescribed benzodiazepines daily without interruption to maintain steady-state plasma concentrations ____ 24. What nursing assessment finding indicates a common anticholinergic side effect requiring intervention in patients receiving antiparkinson therapy? a. The patient demonstrates miosis and increased gastrointestinal motility requiring pupil assessment and dietary modification interventions c. The patient demonstrates bradycardia and excessive lacrimation requiring cardiac monitoring and ophthalmologic consultation for treatment b. The patient reports experiencing urinary frequency and excessive salivation requiring fluid restriction and oral care interventions d. The patient reports urinary retention and dry mouth requiring bladder assessment and increased fluid intake recommendations ____ 25. What mechanism of action describes the therapeutic effect of proparacaine and tetracaine when administered for ophthalmic procedures? a. Proparacaine and tetracaine constrict blood vessels in the conjunctiva to decrease ocular inflammation and hyperemia c. Proparacaine and tetracaine inhibit carbonic anhydrase enzymes in the ciliary body to reduce intraocular pressure b. Proparacaine and tetracaine stimulate parasympathetic receptors in the corneal epithelium to produce mydriasis and cycloplegia d. Proparacaine and tetracaine locally block pain signals at the eye's nerve endings to provide corneal anesthesia ____ 26. What clinical condition represents an appropriate use for a direct-acting cholinergic agonist medication such as bethanechol? a. Treatment of bradycardia and decreased heart rate to restore normal cardiac rhythm by stimulating muscarinic receptors in cardiac tissue c. Treatment of urinary retention and neurogenic bladder by stimulating muscarinic receptors in the detrusor muscle to promote bladder contraction b. Preoperative preparation to decrease salivary secretions and increase heart rate during surgical procedures requiring general anesthesia d. Treatment of cholinesterase inhibitor poisoning and muscarinic agonist overdose by blocking excessive acetylcholine accumulation at receptor sites ____ 27. What cognitive and functional deficits characterize the mild cognitive impairment phase of Alzheimer disease progression? a. The patient demonstrates advanced neurological deterioration with loss of motor function and complete inability to perform any purposeful movements c. The patient demonstrates complete loss of verbal communication with incontinence and requires total assistance for all self-care activities b. The patient demonstrates subtle memory changes with preserved independence in activities of daily living and minimal functional impairment d. The patient demonstrates severe memory loss with complete dependence for activities of daily living and inability to recognize family members ____ 28. What cardiovascular side effect is commonly associated with carbidopa-levodopa therapy during early treatment of Parkinson disease? a. Carbidopa-levodopa causes hypertensive crisis and decreased heart rate requiring immediate discontinuation of therapy and emergency intervention c. Carbidopa-levodopa causes bradycardia and peripheral vasoconstriction requiring continuous cardiac monitoring during initial dosing periods b. Carbidopa-levodopa causes orthostatic hypotension and increased heart rate requiring patient education about position changes and fall prevention d. Carbidopa-levodopa causes atrial fibrillation and ventricular dysrhythmias requiring prophylactic antiarrhythmic medication administration before treatment ____ 29. What characteristic distinguishes myoclonic seizures from other seizure types in terms of motor manifestations and consciousness level? a. Myoclonic seizures involve repetitive purposeless movements and altered awareness lasting one to two minutes with gradual recovery c. Myoclonic seizures involve sudden loss of muscle tone causing falls to the ground with brief loss of consciousness b. Myoclonic seizures involve sustained muscle rigidity followed by rhythmic jerking movements with complete loss of consciousness throughout d. Myoclonic seizures involve brief jerking or stiffening movements of extremities lasting seconds with consciousness typically maintained throughout ____ 30. What patient teaching instruction should the nurse include when educating a patient prescribed bethanechol for urinary retention? a. Take the medication with meals to enhance absorption and minimize gastrointestinal side effects such as cramping and diarrhea c. Take the medication on an empty stomach one to two hours before meals to minimize nausea and vomiting b. Expect decreased salivation and dry mouth as common side effects that will resolve after several days of therapy d. Monitor for increased heart rate and palpitations as expected therapeutic responses to the medication ____ 31. What mechanism of action distinguishes direct-acting cholinergic agonists from indirect-acting cholinergic agonists? a. Direct-acting agonists break down acetylcholine into choline and acetic acid rapidly, while indirect-acting agonists prevent the synthesis of new acetylcholine molecules c. Direct-acting agonists stimulate nicotinic receptors exclusively in skeletal muscle tissue, while indirect-acting agonists stimulate both muscarinic and nicotinic receptors simultaneously b. Direct-acting agonists inhibit the enzyme cholinesterase to allow acetylcholine accumulation at receptor sites, while indirect-acting agonists bind directly to muscarinic receptors d. Direct-acting agonists bind to and activate cholinergic receptors to produce tissue responses, while indirect-acting agonists inhibit cholinesterase to permit acetylcholine accumulation ____ 32. What characteristic distinguishes rapid eye movement sleep from non-rapid eye movement sleep in the normal sleep cycle? a. REM sleep occurs continuously for 25 years cumulatively while NREM sleep occurs intermittently between waking periods c. REM sleep follows the four stages of NREM sleep and completes one full sleep cycle at approximately 90-minute intervals b. REM sleep follows the four stages of NREM sleep and completes one full sleep cycle at approximately 90-minute intervals d. REM sleep occurs in four progressively deeper stages before transitioning to NREM sleep at 90-minute intervals ____ 33. What cardiovascular response occurs when a patient receives a cholinergic agonist medication compared to a cholinergic antagonist medication? a. Cholinergic agonists increase heart rate by stimulating muscarinic receptors, while cholinergic antagonists decrease heart rate by blocking nicotinic receptors at cardiac tissue c. Cholinergic agonists dilate pupils and increase pulse rate, while cholinergic antagonists constrict pupils and decrease gastrointestinal motility through opposite receptor mechanisms b. Cholinergic agonists increase bladder contraction and salivation, while cholinergic antagonists produce identical effects through stimulation of acetylcholinesterase enzyme activity d. Cholinergic agonists decrease heart rate by stimulating muscarinic receptors, while cholinergic antagonists increase heart rate by blocking parasympathetic nervous system effects ____ 34. What gastrointestinal side effects are most commonly associated with acetylcholinesterase inhibitors used in Alzheimer disease treatment? a. Acetylcholinesterase inhibitors cause nausea, vomiting, diarrhea, and abdominal cramps requiring monitoring for dehydration and nutritional status c. Acetylcholinesterase inhibitors cause paralytic ileus and bowel obstruction requiring immediate surgical consultation and nasogastric tube placement b. Acetylcholinesterase inhibitors cause gastric ulceration and gastrointestinal bleeding requiring prophylactic proton pump inhibitor therapy administration d. Acetylcholinesterase inhibitors cause constipation and decreased bowel motility requiring administration of stool softeners and dietary fiber supplementation ____ 35. What pharmacological action differentiates methylphenidate from amphetamines in the treatment of attention-deficit/hyperactivity disorder? a. Methylphenidate blocks muscarinic receptors in the prefrontal cortex, while amphetamines enhance gamma-aminobutyric acid transmission in the limbic system c. Methylphenidate suppresses acetylcholine synthesis in the basal ganglia, while amphetamines stimulate histamine release from hypothalamic neurons b. Methylphenidate inhibits the reuptake of dopamine and norepinephrine and augments serotonin action, while amphetamines stimulate neurotransmitter release and block reuptake d. Methylphenidate activates nicotinic cholinergic receptors in the cerebral cortex, while amphetamines inhibit monoamine oxidase enzyme activity ____ 36. What gastrointestinal effect differentiates cholinergic agonists from cholinergic antagonists when administered to patients? a. Cholinergic agonists decrease gastrointestinal motility and reduce salivation, while cholinergic antagonists increase gastrointestinal motility and stimulate excessive salivation c. Cholinergic agonists produce mydriasis and decreased bladder contraction, while cholinergic antagonists produce miosis and increased bladder contraction b. Cholinergic agonists increase gastrointestinal motility and salivation, while cholinergic antagonists decrease gastrointestinal motility and reduce salivation d. Cholinergic agonists cause urinary retention and pupillary constriction, while cholinergic antagonists cause increased micturition and pupillary dilation ____ 37. What mechanism of action differentiates COMT inhibitors from MAO-B inhibitors in prolonging dopamine activity for Parkinson disease treatment? a. COMT inhibitors reduce acetylcholine effects in the brain while MAO-B inhibitors enhance gamma-aminobutyric acid neurotransmission c. COMT inhibitors block the enzyme that inactivates dopamine while MAO-B inhibitors prevent the breakdown of dopamine through catabolism b. COMT inhibitors promote dopamine synthesis from levodopa while MAO-B inhibitors block dopamine reuptake at synaptic terminals d. COMT inhibitors stimulate dopamine receptor activation directly while MAO-B inhibitors increase acetylcholine metabolism in the striatum ____ 38. What drug interaction requires avoidance when prescribing methylphenidate for attention-deficit/hyperactivity disorder? a. Concurrent use with calcium channel blockers within 10 days due to risk of complete heart block and ventricular dysrhythmias c. Concurrent use with beta-adrenergic blockers within 21 days due to risk of profound bradycardia and cardiac arrest b. Concurrent use with selective serotonin reuptake inhibitors within 7 days due to risk of serotonin syndrome and neurotoxicity d. Concurrent use with monoamine oxidase inhibitors within 14 days due to risk of hypertensive crisis and severe blood pressure elevation ____ 39. What adverse effect requires immediate nursing intervention when a patient receiving neostigmine develops severe muscle weakness and increased respiratory difficulty? a. Myasthenic crisis resulting from inadequate acetylcholinesterase inhibitor dosing that requires administration of additional neostigmine to relieve symptoms c. Anticholinergic toxicity resulting from excessive muscarinic receptor blockade that requires administration of physostigmine to reverse symptoms b. Nicotinic receptor desensitization resulting from prolonged acetylcholine exposure that requires administration of edrophonium to restore function d. Cholinergic crisis resulting from acetylcholinesterase inhibitor overdosing that requires administration of atropine sulfate as the antidote ____ 40. What dosing principle guides methylphenidate therapy for children with attention-deficit/hyperactivity disorder? a. Dosage should be maximal at treatment initiation to achieve rapid symptom control and prevent behavioral escalation c. Dosage should be minimal in controlling ADHD symptoms to reduce potential for adverse effects and drug dependence b. Dosage should be weight-based using standardized calculations to ensure therapeutic plasma concentrations across all age groups d. Dosage should be fixed regardless of symptom response to maintain consistent receptor occupancy and prevent tolerance development
Student Cоde оf Cоnduct NOVA is а leаrning community with specific expectаtions concerning the conduct of its students. The College’s approach to student learning and student conduct is to provide a safe and supportive learning environment that promotes teaching, learning and student success. When a student’s conduct adversely affects the College’s pursuit of its educational objectives, actions will be taken to remedy the situation. NOVA’s approach will be to resolve the problem and to help students learn to make better decisions. It is the College’s goal that when students experience the conduct process, they will leave that process as better educated students, better all-around members of the College community, and better global citizens. In accord with this general philosophy, efforts will be made to resolve discipline issues informally where possible. By enrolling at NOVA, a student accepts its policies and procedures and acknowledges the right of NOVA to take action, up to and including suspension or expulsion in response to misconduct. It is a student’s responsibility to become familiar with the student code of conduct. Lack of awareness is no excuse for noncompliance with NOVA’s policies and procedures. Directions Read the Student Code of Conduct above and the Course Syllabus under the Course Home. To confirm that you have read and agree to abide by the Student Code of Conduct and syllabus type your name in the textbox below.